- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study, Pneumococcal 13-valent Conjugate Vaccine, Quality-of-Life Assessment, Trivalent Influenza Vaccine
- Biological · Drug · Other
- Lead sponsor
- Jennifer Woyach
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 481–504
of 1,164
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Influenza
- Interventions
- Inactivated Influenza A Vaccine A/H5N1, Placebo (IM), Placebo (ID)
- Biological · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 227 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Influenza, Human
- Interventions
- FLU Q-PAN H5N8 375_B, FLU Q-PAN H5N8 375_A, FLU Q-PAN H5N8 750_B, FLU Q-PAN H5N8 750_A
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 518 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 20
- States / cities
- Anniston, Alabama • Mobile, Alabama • Tempe, Arizona + 17 more
- Conditions
- Seasonal Influenza
- Interventions
- mRNA-1011.1, mRNA-1011.2, mRNA-1012.1, mRNA-1010, mRNA-1010.2, mRNA-1010.3
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 698 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 22
- States / cities
- Lakewood, California • Long Beach, California • Fort Collins, Colorado + 19 more
- Conditions
- Influenza
- Interventions
- Flublok, Flucelvax, Fluarix, Fluzone, Fluzone High-Dose
- Biological
- Lead sponsor
- Centers for Disease Control and Prevention
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 944 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Temple, Texas
- Conditions
- Corona Virus Infection, Flu Vaccine, Immunity
- Interventions
- Flu shot
- Biological
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 9 Years to 64 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2028
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Childhood Influenza Vaccination, School-located Influenza Vaccination
- Interventions
- School-located Influenza Vaccination Clinic
- Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 4 Years to 19 Years
- Enrollment
- 20,461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Influenza
- Interventions
- Flufirvitide 3, Placebo for Flufirvitide-3
- Drug
- Lead sponsor
- Autoimmune Technologies, LLC
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Spartanburg, South Carolina
- Conditions
- Influenza, COVID-19
- Interventions
- Influenza and COVID-19 Combination A, Licensed influenza vaccine, COVID-19 Vaccine, Influenza and COVID-19 Combination B, Placebo, Investigational influenza vaccine
- Biological
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 8,795 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 106
- States / cities
- Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 76 more
- Conditions
- Influenza
- Interventions
- Fluarix, adjuvanted influenza vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,350 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 10
- States / cities
- Clearwater, Florida • Coral Gables, Florida • Milford, Massachusetts + 7 more
- Conditions
- Inflammatory Bowel Disease (IBD), Immunosuppressed or Non-Immunosuppressed, Influenza Vaccine, Antibody Titers, Seroprotective Titers
- Interventions
- blood draw
- Other
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Vaccine Refusal
- Interventions
- educational intervention
- Behavioral
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- Not listed
- Enrollment
- 510 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Influenza
- Interventions
- Fluarix, Fluzone
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Months to 35 Months
- Enrollment
- 3,317 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 58 more
- Conditions
- Influenza
- Interventions
- Atorvastatin, Placebo
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Influenza, Immunization, Older Adults, Over Age 75
- Interventions
- Influenza
- Biological
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 75 Years and older
- Enrollment
- 1,025 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Influenza
- Interventions
- Baloxavir Marboxil
- Drug
- Lead sponsor
- Tricore, Inc
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 25 participants
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Influenza A Subtype H7N7 Infection
- Interventions
- Monovalent Influenza Subvirion Vaccine, H7N7
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Healthy
- Interventions
- Entolimod, Placebo, Influenza vaccine
- Drug
- Lead sponsor
- Robert J. Pignolo
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Influenza
- Interventions
- Flublok Quadrivalent, Inactivated Influenza Vaccine (IIV4)
- Biological
- Lead sponsor
- Protein Sciences Corporation
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 1,350 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 10
- States / cities
- Sacramento, California • Coral Gables, Florida • Savannah, Georgia + 7 more
- Conditions
- Influenza, Vaccination, Health Promotion, Health Behavior, Risk Reduction
- Interventions
- Reminder, Risk reduction, Medical records-based recommendation, Algorithm-based recommendation
- Behavioral
- Lead sponsor
- National Bureau of Economic Research, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45,061 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Danville, Pennsylvania
- Conditions
- High Risk for Serious Influenza, High Risk for Pneumonia
- Interventions
- Influenza vaccination, Pneumococcal polysaccharide vaccination
- Biological
- Lead sponsor
- Louisiana State University Health Sciences Center in New Orleans
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 2
- States / cities
- Baton Rouge, Louisiana
- Conditions
- Influenza A Subtype H5N1 Infection
- Interventions
- Seasonal Influenza Vaccine
- Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
- Conditions
- Influenza
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 65 Years to 99 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Influenza
- Interventions
- Flufirvitide-3 0.05 mg single dose, Flufirvitide-3, 0.1 mg single dose, Flufirvitide-3, 0.2 mg single dose, Flufirvitide-3, 0.4 mg single dose, Placebo
- Drug · Other
- Lead sponsor
- Autoimmune Technologies, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas